Enhancing the Anticancer Efficacy of Decitabine via β-Hydroxybutyrate in Colorectal and Prostate Cancers Cell Lines

Background: Epigenetic targeting therapy, including histone deacetylase (HDAC) inhibitors and DNA-methyltransferase 1 (DNMT1) inhibitors, is a promising and attractive tool to treat advanced cancers, overcome drug resistance, and minimize adverse effects of traditional therapies. Objective: To investigate whether β-hydroxybutyrate enhanced the effectiveness of decitabine against colon cancer and enhanced the anti-cancer effect of decitabine against colon and prostate cancer cell lines. Methods: LS174T cells (colorectal cancer) and PC3 cells (prostate cancer) were seeded in a 96-well cell culture plate. Decitabine was used in six [100, 50, 25, 12.5, 6.25, & 3.125μg/ml] concentrations alone and combined with β-hydroxybutyrate, enhancing the effectiveness of decitabine against colon (2000μg/ml). After 48 hours of incubation, LS174T cells and PC3 cell viability were determined by MTT assay. DNMT1-enzyme level was measured using the DNMT1-ELISA kit. Results: For the LS174T cell line and PC3 cell line, the combination of decitabine plus β-hydroxybutyrate enhanced the effectiveness of decitabine against colon and showed a significant (p<0.05) decrease in viability percent for all concentrations compared to the control group. Also, the comparison between decitabine monotherapy and decitabine plus β-hydroxybutyrate enhanced the effectiveness of decitabine against colon and revealed a significant (p<0.05) difference in viability between the two groups. Finally, a significant (p<0.05) reduction in DNMT1 level was observed between monotherapy and combination therapy for all decitabine concentrations and for both cell lines. Conclusions: β-hydroxybutyrate enhanced the effectiveness of decitabine against colon and prostate cancers, suggesting that β-hydroxybutyrate may serve as a promising adjuvant to decrease decitabine therapeutic doses.

Authors

Institutions

Publication Details

Journal
Al-Rafidain Journal of Medical Sciences
Published
2026-11-15
DOI
https://doi.org/10.54133/ajms.v11i2.3363
Primary Topic
Epigenetics and DNA Methylation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Enhancing the Anticancer Efficacy of Decitabine via β-Hydroxybutyrate in Colorectal and Prostate Cancers Cell Lines

Bassim I. Mohammad, Fadhil Abduljabbar Rizij, Rana Ayad Ghaleb, Najah Rayish Hadi et al.
Al-Rafidain Journal of Medical Sciences
Epigenetics and DNA Methylation
article

Enhancing the Anticancer Efficacy of Decitabine via β-Hydroxybutyrate in Colorectal and Prostate Cancers Cell Lines

Bassim I. Mohammad, Fadhil Abduljabbar Rizij, Rana Ayad Ghaleb, Najah Rayish Hadi, Sarah Khudhair Obayes
article en

Abstract

Background: Epigenetic targeting therapy, including histone deacetylase (HDAC) inhibitors and DNA-methyltransferase 1 (DNMT1) inhibitors, is a promising and attractive tool to treat advanced cancers, overcome drug resistance, and minimize adverse effects of traditional therapies. Objective: To investigate whether β-hydroxybutyrate enhanced the effectiveness of decitabine against colon cancer and enhanced the anti-cancer effect of decitabine against colon and prostate cancer cell lines. Methods: LS174T cells (colorectal cancer) and PC3 cells (prostate cancer) were seeded in a 96-well cell culture plate. Decitabine was used in six [100, 50, 25, 12.5, 6.25, & 3.125μg/ml] concentrations alone and combined with β-hydroxybutyrate, enhancing the effectiveness of decitabine against colon (2000μg/ml). After 48 hours of incubation, LS174T cells and PC3 cell viability were determined by MTT assay. DNMT1-enzyme level was measured using the DNMT1-ELISA kit. Results: For the LS174T cell line and PC3 cell line, the combination of decitabine plus β-hydroxybutyrate enhanced the effectiveness of decitabine against colon and showed a significant (p<0.05) decrease in viability percent for all concentrations compared to the control group. Also, the comparison between decitabine monotherapy and decitabine plus β-hydroxybutyrate enhanced the effectiveness of decitabine against colon and revealed a significant (p<0.05) difference in viability between the two groups. Finally, a significant (p<0.05) reduction in DNMT1 level was observed between monotherapy and combination therapy for all decitabine concentrations and for both cell lines. Conclusions: β-hydroxybutyrate enhanced the effectiveness of decitabine against colon and prostate cancers, suggesting that β-hydroxybutyrate may serve as a promising adjuvant to decrease decitabine therapeutic doses.

Al-Rafidain Journal of Medical SciencesVol. 11(2)
University of Babylon (IQ), University of Al-Qadisiyah (IQ), University of Kufa (IQ)
Epigenetics and DNA Methylation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon